

November 14, 2022

To, The Manager Listing Department, **The National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Monday, November 14, 2022

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we Zota Health Care Limited (the "Company") would like to inform you that the Board of Directors of the Company in its Meeting held on Monday, November 14, 2022 at 11:00 A.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002, Gujarat, have *inter alia*, discussed and approved the following business:

 Considered and approved standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2022 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure – 1).

The unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at <u>www.nseindia.com</u> and on Company's website at <u>www.zotahealthcare.com</u>

The Board meeting concluded at 1:10 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

Ashvin Variya (Company Secretary & Compliance Officer) Place: Surat

Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: <u>info@zotahealthcare.com</u> Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Annexure -1

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

То

The Board of Directors of Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Zota Health Care Limited (the "Company") for the quarter and half year ended September 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

1arc

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Shivangi Parekh & Co. Chartered Accountants ICAI FRN: 131449W

10

CA. Shivangi Mehta Proprietor M. No.118936 UDIN: 22118936 BDA I J09599

Date: 14/11/2022 Place: Surat

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.



| | healthcare Itd. | Quarter Ended | | | (₹ in Lakhs, except per share dat Half Year Ended Year Ended | | |
|-------|--|---------------|---------------|-------------|---|--------------------|------------------|
| | Particulars | | 30-06-2022 | 30-09-2021 | 30-09-2022 30-09-2021 | | 31-03-2022 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1. | Revenue from Operations | 3857.26 | 2040 70 | 0500 70 | | | |
| II. | Other Income | 98.43 | 2948.78 | 3539.70 | 6806.04 | 6884.19 | 13153.3 |
| | other income | 98.43 | 54.18 | 18.04 | 152.61 | 48.52 | 164.5 |
| Ш. | Total Income | 3955.69 | 3002.97 | 3557.74 | 6958.66 | 6932.71 | 13317.8 |
| IV. | Expenses: | | | | | | E. |
| | Cost of Materials Consumed | 561.39 | 635.56 | 593.72 | 1106.05 | 1162.00 | 1005 6 |
| | Purchases of Stock-in-Trade | 1842.35 | 1334.88 | 1675.31 | 1196.95 3177.23 | 1162.86 3100.17 | 1996.9 6608.4 |
| | Changes in Inventories of Finished Goods, Work-in-Progress and | 1012.00 | 1554.00 | 10/5.51 | 5177.25 | 5100.17 | 0008. |
| | Stock-in-Trade | 21.53 | (121.56) | 73.44 | (100.04) | 285.98 | 148.4 |
| | Employee Benefit Expenses | 249.40 | 256.59 | 224.49 | 505.99 | 485.82 | 986. |
| | Finance Costs | 2.59 | 1.64 | 1.19 | 4.23 | 2.07 | 7.3 |
| | Depreciation / Amortisation and Depletion Expense | 57.36 | 55.96 | 66.02 | 113.32 | 127.70 | 273. |
| | Other Expenses | 659.97 | 637.17 | 479.12 | 1297.14 | 867.11 | 1877.5 |
| | Total Expenses | 3394.58 | 2800.25 | 3113.28 | 6194.83 | 6031.71 | 11898.7 |
| 17 | perfection from the second second | | | | | | |
| V. | Profit before Exceptional items and tax from continuing operations (III-IV) | | 202 72 | | | | |
| VI. | Exceptional Items | 561.11 | 202.72 | 444.47 | 763.83 | 901.00 | 1419. |
| VII. | Profit/(loss) before tax | 561.11 | 202.72 | 444.47 | - 763.83 | 901.00 | 1410 |
| /111. | Tax Expense: | 501.11 | 202.72 | 444.47 | /05.85 | 901.00 | 1419. |
| | (1) Current tax | 137.86 | 51.84 | 113.45 | 189.70 | 229.38 | 369. |
| | (1.1) I.T. & DD Tax Provision Created Short/ excess | - | - | - | | | (0. |
| | (2) Deferred Tax | (0.86) | (4.47) | 0.62 | (5.33) | (2.58) | 7.3 |
| IX. | Profit/ (Loss) for the period from Continuing | | | | | | |
| | Operations (VII-VIII) | 422.40 | 146.41 | 331.63 | 568.81 | 669.04 | 1058.0 |
| Х. | Profit/(loss) before tax from discontinued operations | | - | | 500.01 | 005.04 | 1050. |
| XI. | Tax Expense of discontinued Operations | 17.556 | .63 | | | - | |
| a. | Profit/ (Loss) from Discontinued Operations (after Tax) | 100.00 | | | 1.5 | - | |
| | (X- XI) | | | | - | | |
| 30. | Profit/ (Loss) for the period | 422.40 | 146.41 | 331.63 | 568.81 | 669.04 | 1058.0 |
| IV. | Other Comprehensive Income | 01000000000 | 5256525553669 | | | | 2000. |
| | A (i) Items that will not be reclassified to Statement of | | | | | | |
| | profit and loss | 5.55 | 8.46 | (20.81) | 14.01 | 0.02 | 18. |
| | (ii) Income Tax relating to items that will not be | | Rectances. | | a. 50 | | |
| | reclassified to Statement of profit and loss | (1.40) | (2.13) | 5.24 | (3.53) | * | (4. |
| | B (i) Items that will be reclassified to Statement of profit and loss | | | (3)) | | | |
| | (ii) Income Tax relating to items that will be reclassified | | | | 25 | | |
| | to profit and loss | | | 52 S | | | |
| | Other comprehensive income for the period, net of tax | 4.16 | 6.33 | (15.57) | 10.48 | 0.01 | 19.6 |
| | Total comprehensive income for the period (XIII + XIV) | 426.55 | 152.74 | 316.05 | 579.29 | 669.05 | 13.8 |
| | Paid-up Equity Share Capital | 2516.03 | 2516.03 | 2516.03 | 127752072522 | 64.000 CT + 190-20 | |
| | Other Equity | 2510.03 | 2010.03 | 2510.03 | 2516.03 | 2516.03 | 2516.0 |
| | Earnings per equity share of face value of 10 each | | | | | | 6621.4 |
| | (1) Basic (in ₹) | 1.68 | 0.58 | 1.34 | 2.26 | 2.72 | 4.2 |
| | (2) Diluted (in ₹) | 1.68 | 0.58 | 1.34 | 2.26 | 2.72 | 4.1 |

denotes figures less than a lakh For and on behalf of the Board

(A2)

(Whole Time Director) Himanshu M. Zota (Din: 01097722)

Company Secretary Ashvin Variya

Date: 14-11-2022 Place : Surat **Registered Office :**

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

F



Plant :



Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

For Shivangi Parekh & Co. **Chartered Accountants** Firm No. 131449W

CA. Shivangi Mehta Proprietor M. No. 118936

d

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of Zota Health Care Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Zota Health Care Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter and half year ended September 30, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)
- b. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)



Pare

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total assets of Rs. 4808.36 Lakhs as at September 30, 2022, total revenues of Rs. 275.85 Lakhs and Rs.417.30 Lakhs, total net loss of Rs. 332.50 Lakhs and Rs.558.12 Lakhs and total comprehensive loss of Rs. 317.75 Lakhs and Rs.531.29 Lakhs, respectively for the quarter and half year ended September 30, 2022, and net cash flows of Rs. 8.29 Lakhs for the half year ended September 30, 2022 as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

are

For Shivangi Parekh & Co. **Chartered Accountants** ICAI FRN: 131449W

CA. Shivangi Mehta Proprietor M. No.118936

UDIN: 22118936BDAJPU2225

302, SAI BHAVAN, NR. NEW SAIBABA TEMPLE, OPP. SMC MULTILEVEL PARKING, SHAHPORE,

SURAT-395002.

Date: 14/11/2022 Place: Surat



ZOTA HEALTH CARE LIMITED

and all the second s

| e | althcare itd. | Quarter Ended | | | (₹ in Lakhs, except per share data Half Year ended Year Ende | | |
|---|--|---------------|----------------|--------------------|---|--------------|------------------|
| | | | | 30-09-2021 | 30-09-2022 | 30-09-2021 | 31-03-202 |
| | Particulars | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | Revenue from Operations | 3895.08 | 2919.14 | 3538.80 | 6814.21 | 6883.19 | 13119.3 |
| • | Other Income | 84.06 | 47.33 | 17.76 | 131.38 | 48.12 | 163.0 |
| | Total Income | 3979.13 | 2966.46 | 3556.57 | 6945.59 | 6931.31 | 13282.3 |
| | Expenses: | | | | | | |
| | Cost of Materials Consumed | 561.39 | 635.56 | 593.72 | 1196.95 | 1162.86 | 1996.9 |
| | Purchases of Stock-in-Trade | 1842.35 | 1334.88 | 1675.31 | 3177.23 | 3100.17 | 6608.4 |
| | Changes in Inventories of Finished Goods, Work-in-Progress and Stock- | | 00000000000000 | 1 posta - portanar | 0.0000000000 | | |
| | in-Trade | (56.49) | (203.11) | 62.18 | (259.60) | 267.72 | 56. |
| | Employee Benefit Expenses | 277.08 | 275.79 | 233.55 | 552.88 | 497.59 | 1024. |
| | Finance Costs | 66.31 | 37.85 | 1.23 | 104.16 | 2.12 | 32.0 |
| | Depreciation / Amortisation and Depletion Expense | 286.61 | 191.32 | 68.29 | 477.93 | 130.74 | 367. |
| | Other Expenses | 787.31 | 731.75 | 488.23 | 1519.06 | 880.37 | 1953.4 |
| | Total Expenses | 3764.56 | 3004.05 | 3122.50 | 6768.62 | 6041.58 | 12038.8 |
| | Profit before Exceptional items and tax from continuing operations | 17000000000 | 8722172-0 | | | | |
| | (III-IV) Exceptional Items | 214.57 | (37.59) | 434.06 | 176.98 | 889.73 | 1243.4 |
| | Profit/(loss) before tax | 214.57 | (37.59) | 434.06 | 176.98 | - 889.73 | 1242.4 |
| | Tax Expense: | 221137 | (57.55) | 434.00 | 170.96 | 009.73 | 1243.4 |
| | (1) Current tax | 137.86 | 51.84 | 113.45 | 189.70 | 229.38 | 369.0 |
| | (1.1) I.T. & DD Tax Provision Created Short/ excess | | - | - | | - | (0.1 |
| | (2) Deferred Tax | 13.89 | 7.57 | 0.62 | 21.46 | (2.58) | 16.1 |
| | Profit/ (Loss) for the period from Continuing | 22020 | Y2.84533. | | | | |
| | Operations (VII-VIII) | 90.60 | (81.86) | 321.23 | 8.74 | 657.77 | 890.7 |
| | Profit/(loss) before tax from discontinued operations | 2 | * | 19 | - | 2 | |
| 1 | Tax Expense of discontinued Operations | • | 20 | : : | | 8 | |
| | Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI) | | | 3 2 | 12 | 5 | |
| 1 | Profit/ (Loss) for the period | 90.60 | (81.86) | 321.23 | 8.74 | 657.77 | |
| | Other Comprehensive Income | 50.00 | (01.00) | 521.23 | 8.74 | 657.77 | 890.7 |
| 1 | A (i) Items that will not be reclassified to Statement of | | | | | | |
| | profit and loss | 5.55 | 8.46 | (20.81) | 14.01 | 0.02 | 18.4 |
| | (ii) Income Tax relating to items that will not be | 1.000 | | 15-74-74-74 | 2762-222 | | |
| | reclassified to Statement of profit and loss B (i) Items that will be reclassified to Statement of profit | (1.40) | (2.13) | 5.24 | (3.53) | • | (4.6 |
| | and loss | (0.01) | 0.06 | | 0.05 | * | |
| | (ii) Income Tax relating to items that will be reclassified | * 27 A. C. | 10100 | | 0.05 | 22 | |
| | to profit and loss | • | (0.01) | * | (0.01) | | |
| | Other comprehensive income for the period, net of tax | 4.15 | 6.37 | (15.57) | 10.52 | 0.02 | 13.8 |
| | Total comprehensive income for the period (XIII + XIV) | 94.75 | (75.49) | 305.65 | 19.26 | 657.78 | 904.5 |
| | Profit attributable to: | | | | | | |
| | Owners of the parent | 90.60 | (81.86) | 321.23 | 8.74 | 657.77 | 200.7 |
| | Non-controlling interest | - | (, | - | 0.74 | | 890.7 |
| | Other comprehensive income attributable to: | | | | | | |
| | Owners of the parent | 4.15 | 6.37 | (15.57) | 10.52 | 0.00 | |
| | Non-controlling interest | | - | (15.57) | 10.52 | 0.02 | 13.8 |
| | Total Comprehensive Income attributable to: | | | | | | |
| | Owners of the parent | 94.75 | (75.49) | 205 65 | 10.20 | (| |
| | Non-controlling interest | | (75.49) | 305.65 | 19.26 | 657.78 | 904.5 |
| | Paid-up Equity Share Capital | 2516.02 | 3545.00 | | 1000000000 | - 20 million | |
| | Other Equity Share Capital | 2516.03 | 2516.03 | 2516.03 | 2516.03 | 2516.03 | 2516.0 6446.6 |
| | Earnings per equity share of face value of `10 each | | | | | | 0440.0 |
| | (1) Basic (in ₹) | 0.36 | (0.33) | 1.30 | 0.03 | 2.02 | |
| | (2) Diluted (in ₹) | 0.36 | (0.33) | 1.30 | 0.03 | 2.67 | 3.5 3.5 |

denotes figures less than a lakh For and on behalf of the Board

Heers

(Whole Time Director) Himanshu M. Zota (Din: 01097722)

(Managing Director) Moxesh K. Zota (Din: 07625219)

VSZ

FL La

Company Secretary Chief Financial Officer Ashvin Variya Viral Mandviwala Date: 14-11-2022

Registered Office^{Place : Surat}

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

Plant :

*

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

0

Parek

0

ane

SURA

ered Acco

For Shivangi Parekh & Co.

Chartered Accountants

Firm No. 131449W hzer

CA. Shivangi Mehta Proprietor M. No. 118936

01



Notes:

- 1. The above financial results for the quarter and half year ended September 30, 2022 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on November 14, 2022.
- 2. The financial results have been prepared in accordance with the Indian Account Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
- 3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2022.
- 4. The Company has made assessment of the possible effects of COVID-19 pandemic on its current and future operations, liquidity position and cash flow using internal and external sources of information. The Company is continuously monitoring the impact of COVID-19 and does not see any significant impact on its operations and financial position as at September 30, 2022.
- 5. The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
- 6. The consolidated results include the result of following wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt.) Ltd.
 - ii) DAVAINDIA HEALTH MART LIMITED
- 7. In the consolidated financial results, the Company has adopted Ind AS 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 3497.81 lakhs and a corresponding Lease Liability of Rs. 3595.12 lakhs as at September 30, 2022. The impact of this on the consolidated profit for the quarter ended September 30, 2022 is Rs. 39.81 lakhs.
- 8. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.





Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED Unaudited Cash Flow Statement For the Half Year Ended 30th September, 2022

| - | ZOTO Unaudited Cash Flow State | | Concellul | | | Amount ₹ in Laki | |
|---|---|---------|---|--|--|--|--|
| | healthcare Itd. | | Consolidated Half year ended Half year ended | | Standalone | | |
| | PARTICULARS | | 30-09-2022 (Unaudited) | Half year ended 30-09-2021 (Unaudited) | Half year ended 30-09-2022 (Unaudited) | Half year ended 30-09-2021 (Unaudited) | |
| A | CASH FLOW FROM OPERATING ACTIVITIES Net Profit Before Tax as per Statement of Profit and Loss Adjusted for: | | 176.98 | 889.73 | 763.83 | 90 | |
| | Exceptional items | | - | - | | | |
| | Depreciation / Amortisation and Depletion Expense | | 477.93 | 130.74 | 113.32 | 12 | |
| | Interest on Fixed Deposits | | -57.68 | -26.11 | -79.04 | | |
| | Finance Costs | | 105.14 | - | 6.23 | | |
| | Operating Profit before Working Capital Changes Adjusted for: | | 702.37 | 994.36 | 804.35 | 100 | |
| | Trade Payables | 3 | 277.82 | 604.88 | 220.19 | 55 | |
| | Provisions-Current Liabilities | | 224.81 | 243.50 | 219.08 | 23 | |
| | Provisions - Non-Current | | -11.03 | 9.70 | -11.03 | | |
| | Current Liabilities | | -373.01 | 369.16 | -402.35 | 36 | |
| | Trade Receivables | | 418.97 | -703.27 | -33.49 | -72 | |
| | Loans | | -82.80 | -219.03 | 4.25 | -21 | |
| | Inventories | | -132.21 | 267.55 | 27.36 | 28 | |
| | Other Current Assets | | -757.33 | 75.76 | -645,44 | 8 | |
| | Changes in Working Capital | - | -434.79 | 648.24 | -621.43 | 64 | |
| | Cash Generated from Operations | | 267.58 | 1642.61 | 182.92 | 164 | |
| | Taxes Paid | - | -186.17 | -229.38 | -193.22 | -22 | |
| | Net Cash Flow from/(Used in) Operating Activities | (A) | 81.41 | 1413.23 | -10.31 | 141 | |
| в | CASH FLOW FROM INVESTING ACTIVITIES | | | | | | |
| | Purchase of Intangible Assets | | -20.56 | -49.31 | -20.56 | -4 | |
| | Decrease in Long Term Loans & Advances | | -0.60 | 2.51 | -632.82 | 1 | |
| | Interest on Fixed Deposits | | 57.68 | 26.11 | 79.04 | 2 | |
| | Interest - others | | -6.23 | - | -6.23 | 1 | |
| | Proceeds from disposal of Property, Plant and Equipment and Intangible Assets | | - | | | | |
| | Purchase of Tangible Assets | | -446.32 | -34.04 | -76.20 | | |
| | Non-current Investments | | 1035.22 | -1419.80 | 1035.29 | -160 | |
| | Net Cash Flow (Used in) Investing Activities | (B) | 619.19 | -1474.52 | 378.52 | -162 | |
| С | CASH FLOW FROM FINANCING ACTIVITIES | | | | | | |
| | Add: Adjustment for | | | | | | |
| | Proceeds from Issue of Equity Share Capital | | a (| 60.00 | | 6 | |
| | Increase in Securities Premium Reserve | | - | 1620.00 | - | 162 | |
| | Principal payment of lease liability | | -225.24 | | - | 101 | |
| | Interest payment of lease liability | | -98.91 | · · · · | 645 | | |
| | Dividend Paid | | -377.40 | | 277.40 | | |
| | Net Cash Flow from / (Used in) Financing Activities | (C) | -701.56 | 1680.00 | -377.40 - 377. 40 | 168 | |
| | Net Increase/(Decrease) in Cash & Cash Equivalents | (A+B+C) | -0.96 | 1618.71 | -9.20 | 147 | |
| | Opening Balance of Cash and Cash Equivalents | | 270.01 | | | | |
| | | | 229.91 | 134.63 | 220.00 | 13 | |
| | Closing Balance of Cash and Cash Equivalents | | 228.96 | 1753.33 | 210.80 | | |

The accompanying notes are an integral part of the financial statements. As per our report of even date

(Managing Director)

0 0

Moxesh K. Zota

(Din : 07625219)

Viral Mandviwala

For and on behalf of the Board

Kenst

(Whole Time Director) Himanshu M. Zota (Din : 01097722)

Ashvin Variya

(Chief Financial Officer) (Company Secretary)

Date: 14-11-2022 Place: Surat

Registered Office :

Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com



For Shivangi Parekh & Co. **Chartered Accountants** Firm No. 131449W

18hity l

CA. Shivangi Mehta Proprietor M. No. 118936

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122



ZOTA HEALTH CARE LIMITED

Standalone and Consolidated Audited Statement of Assets and Liabilities

| | | Standa | lone | (₹ in Lakhs Consolidated | | |
|------|--|--|--------------------------------------|--|--------------------------------------|--|
| | Particulars | As at 30th September, 2022 Unaudited | As at 31st March, 2022 Audited | As at 30th September, 2022 Unaudited | As at 31st March, 2022 Audited | |
| | ASSETS | | | Vilaguneu | - Autor | |
| (1) | Non-Current Assets | | | | | |
| | Property, plant and equipment | 700.03 | 708.63 | 1185.78 | 893.8 | |
| | Right-of-use assets | - | | 3497.81 | 1469. | |
| | Intangible Assets | 493.68 | 546.88 | 493.68 | 546. | |
| | Capital work-in-progress | 45.23 | | 45.23 | 540. | |
| | Intangible assets under development | - | 5 . | | - | |
| | Financial Assets | | | | | |
| | (i) Investments | 2448.89 | 3484.17 | 2248.44 | 3283. | |
| | (iii) Loans | 893.80 | 260.98 | 10.08 | 9. | |
| | Deferred tax assets (Net) | 1.37 | 6.70 | 36.92 | 15. | |
| | Other Non-current assets | | 0.70 | 30.52 | 15. | |
| | Total Non-Current assets | 4583.00 | 5007.36 | 7517.95 | 6218.3 | |
| (2) | Current Assets | | | 1511.55 | 0218.0 | |
| 1052 | Inventories | 2770.51 | 2797.86 | 3026.89 | | |
| | Financial Assets | | 2757.00 | 3020.85 | 2894.1 | |
| | (i) Trade Receivables | 3865.03 | 3831.54 | 2217.00 | | |
| | (ii) Cash and Cash Equivalents | 1.44 | 0.96 | 3217.66 | 3636. | |
| | (iii) Bank balance other than cash and cash equivalents | 209.36 | 32.5333 | 10.48 | 3. | |
| | (iv) Loans | 660.51 | 219.03 | 218.48 | 226. | |
| | Other Current Assets | | 664.75 | 866.43 | 783. | |
| | Total Current assets | 651.86 | 6.42 | 902.95 | 145.6 | |
| | Total Assets | 8158.70 12741.70 | 7520.57 12527.93 | 8242.89 15760.83 | 7690.4 | |
| (1) | EQUITY AND LIABILITIES Equity (i) Equity Share capital (ii) Other Equity Total Equity (Refer Note 1) | 2516.03 6823.30 | 2516.03 6621.42 | 2516.03 6088.51 | 2516.0 6446.6 | |
| 2) | Liabilities Non-Current Liabilities Financial Liabilities (i) Borrowings | 9339.33 | 9137.45 | 8604.54 | 8962.(| |
| | (ii) Lease liabilities | · · · | 50 C | 3144.60 | - | |
| ſ | Provisions | 91.83 | 102.86 | 93.23 | 1246.3 | |
| | Total non-current liabilities | 91.83 | 102.86 | 3237.83 | 104.2 | |
| | Current liabilities | | 5400533 | 5257.05 | 1350. | |
| | Financial Liabilities | 1 | | | | |
| | (i) Borrowings | 1 | | | | |
| | (ii) Lease liabilities | (原) (1) | 2 | - | 2 | |
| | (ii) Trade payables | | | 450.52 | 243.7 | |
| | | 17 | • | - | 2 | |
| | - Total oustanding dues of micro enterprises and small enterprises | 78.76 | 64.62 | 78.76 | 64.6 | |
| | - Total Oustanding dues of Creditors other than micro enterprises and | | | | | |
| | small enterprises | 1972.94 | 1766.89 | 2068.76 | 1805.0 | |
| | Other Current liabilities | 597.82 | 1000.18 | 646.50 | 1019.5 | |
| | Provisions | 661.01 | 455.94 | 673.94 | 463.1 | |
| | Total current liabilities | 3310.53 | 3287.63 | 3918.47 | 3596.0 | |
| | Total Liabilities | 3402.36 | 3390.48 | 7156.29 | 4946.6 | |
| 8 | Total Equity and Liabilities | 12741.70 | 12527.93 | 15760.83 | 13909.3 | |

Note: 1

Since the subsidiary companies are Wholly Owned Subsidiaries, the non controlling interests is Nil in case of Consolidated Financial Statements and thus, Equity attributable to owners of the Company shall be the same as total equity. For and on behalf of the Board

Kear (Whole Time Director) Himanshu M. Zota (Din: 01097722) MA

Company Secretary Ashvin Variya Date: 14-11-2022 Place : Surat





Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395 002 | Ph: +91 261 2331601 Email: info@zotahealthcare.com Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone, Nr. Sachin Railway Station, Sachin, Surat - 394 230 (Guj.) India Ph: +91 261 2397122

0

Parek

SURA

ed Acco

8

0

ant

For Shivangi Parekh & Co. Chartered Accountants Firm No. 131449W

> CA. Shivangi Mehta Proprietor M. No. 118936